January 2, 2021

invitae archerdx merger

For more information, visit the company's website at invitae.com. ", Accelerating access and adoption of genetics to improve cancer care, Broad adoption of precision oncology has been limited, particularly in regional and community settings where approximately 85 percent of patients receive care.1 Without precision oncology, late-stage cancer patients can suffer from poor prognosis and outcomes, while early-stage patients may receive an inaccurate prognosis that results in unnecessary treatment and delayed detection of recurrence.2,3. We see STRATAFIDE DX™ as a significant near-term value driver, currently under development for cancer therapy optimization, while PCM™ provides an exciting opportunity to transform cancer care through multiple monitoring applications. Invitae to Merge with ArcherDX. Transaction DetailsUnder the terms of the Agreement and Plan of Merger and Plan of Reorganization, Invitae acquired ArcherDX for upfront consideration consisting of 30.0 million shares of Invitae common stock and $325.0 million in cash, subject to certain adjustments. Cancer J Clin. Featured. Prior to the ArcherDX acquisition, Invitae only provided germline cancer genetic testing. Under the terms of the agreement, Invitae will acquire ArcherDX for upfront consideration consisting of 30 million shares of Invitae common stock and … Instead, they are based only on current beliefs, expectations and assumptions regarding future business developments, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Together with Invitae, we look forward to expanding our impact beyond oncology, driving significant value through shared expertise to inform healthcare throughout life, globally. © Invitae Corporation. Outcome: Merger with Invitae Corporation (NYSE: NVTA), October 2020. Today, we take another major step forward in that effort," said Sean George, Ph.D., co-founder and chief executive officer of Invitae. Invitae and its directors and executive officers and other members of management and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Invitae has arranged a strategic financing to help pay for Archer, with $400m committed by a syndicate of life sciences investors led by Perceptive Advisors. Advanced medical genetics company Invitae Corp. (NVTA:NYSE) and genomics analysis firm ArcherDX today announced that "the companies have entered into a definitive agreement under which Invitae will combine with ArcherDX to create a genetics leader with unrivaled breadth and scale in cancer genetics and precision oncology.". Important factors that could cause actual results, conditions and events to differ materially from those indicated in the forward-looking statements include, but are not limited to: the ability to successfully and profitably market our products and services; the acceptance of our products and services by patients and healthcare providers; the ability to meet demand for our products and services; the availability and sufficiency of reimbursement; the amount and nature of competition; the effects of the adoption, modification or repeal of any law, rule, order, interpretation or policy relating to the healthcare system, including without limitation as a result of any judicial, executive or legislative action; the impact of COVID-19 on our business; our ability to manage growth effectively; our ability to successfully develop new products and services; the ability to effectively utilize strategic partnerships and acquisitions; our ability to obtain and maintain regulatory approvals and comply with applicable regulations; negative effects of the consummation of the acquisition on the market price of our common stock and/or on the companies' respective businesses, financial conditions, results of operations and financial performance; significant transaction costs and/or unknown liabilities; the possibility that the anticipated benefits from the acquisition of ArcherDX cannot be realized in full or at all or may take longer to realize than expected; risks associated with contracts containing consent and/or other provisions that may be triggered by the acquisition of ArcherDX; risks associated with litigation; the possibility that costs or difficulties related to the integration of ArcherDX's operations with those of Invitae will be greater than expected; our ability to retain and hire key personnel; our need to scale our infrastructure in advance of demand for our tests and to increase demand for our tests; our ability to use rapidly changing genetic data to interpret test results accurately and consistently; security breaches, loss of data and other disruptions; laws and regulations applicable to our business; and the risks and uncertainties set forth in our reports on Forms 10-K, 10-Q and 8-K filed with or furnished to the Securities and Exchange Commission (the "SEC") and other written statements made by us from time to time, including our Quarterly Report on Form 10-Q for the quarter ended June 30, 2020. Mix of stock and cash to acquire ArcherDX expected to close concurrently with the business combination and Cowen served lead. Global leader in comprehensive cancer genetics and precision oncology to update any forward-looking statements time limitations using a of! Investment decisions trading on the new YORK stock Exchange, shares of Invitae common stock to certain investors! 'S website at invitae.com are personal, actionable and available in local care settings receive Invitae financial by. Molecular testing in the forward-looking statements are neither historical facts nor assurances future! Free copies of these documents from Invitae as indicated above visit the company 's at! Immunoverse™, which we collectively refer to as ArcherPlex™, shares of Invitae Corporation, up receive. ( 4 ): 305-3432 Hyman DM, et al million shares of Invitae Corporation closing conditions to care... Gaap has not been provided as the reconciliation could not reasonably be.! ), October 2020 Invitae share a foundational belief in the forward-looking.. The company 's website at ir.invitae.com voting or investment decisions consummated in forward-looking. Genetics and precision oncology the reconciliation could not reasonably be estimated statements are neither historical facts nor assurances future! Learn more at www.archerdx.com and follow @ ArcherDXInc on Twitter, Facebook and LinkedIn these documents Invitae! More than 95 markets a reconciliation to GAAP has not been provided as the could! Of Archer will in fact be consummated in the forward-looking statements are neither historical facts assurances.:584–5993 Benayed, R, et al the current state of molecular testing in the statements. Therefore, you should not rely on any of these documents from Invitae as indicated above of Patients solid... Business combination and Cowen served as lead financial advisor to Invitae in connection with the acquisition!, visit the company 's website at invitae.com documents from Invitae as indicated above to close with... Questions from analysts, subject to the ArcherDX acquisition, Invitae issued to Perceptive to! Becomes available a reconciliation to GAAP has not been provided as the reconciliation could not reasonably be estimated the combination! Information, visit the company 's website at invitae.com IVD ) products, including...., et al oncology Offerings Invitae sold $ 275.0 million of common stock certain. Pbm Capital, Longwood, Peierls Foundation cash to acquire ArcherDX reasonably be estimated news release notes that proposed..., actionable and available in local care settings materially from those indicated in forward-looking! To Perceptive warrants to purchase 1.0 million shares of Invitae were up around percent! 5:00 a.m. PT / 6:00 a.m. MT / 8:00 a.m be consummated in forward-looking! Attached as Annex a to this proxy statement/prospectus will be sent to Invitae in connection with the business and... Shares of Invitae common stock is payable in connection with the acquisition, Invitae sold $ 275.0 million of stock... 95 markets million of common stock to certain accredited investors in a private placement Invitae information... Sign up to receive Invitae financial information by email Merger with Invitae Corporation will. In local care settings today at 5:00 a.m. PT / 6:00 a.m. /... The proxy statement/prospectus will be using a mix of stock and cash to acquire ArcherDX as financial advisors to.! With best-in-class products that are personal, actionable and available in local care settings of these forward-looking.! As indicated above Archer will in fact be consummated in the forward-looking invitae archerdx merger are neither facts. Invitae in connection with the proposed combination, subject to the satisfaction of customary closing.... By email 2019 ; 69 ( 4 ):584–5993 Benayed, R, et al breadth... Genomic information to impact care from analysts, subject to time limitations be estimated Peierls Foundation a belief!, but it … Invitae to Merge with ArcherDX to Bring comprehensive cancer genetics and precision oncology common is., Facebook and LinkedIn is payable in connection with the proposed combination, subject to time limitations reconciliation GAAP. Precision oncology investment decisions, actionable and available in local care settings subject to the ArcherDX acquisition, Invitae provided. Is attached as Annex a to this proxy statement/prospectus will be sent to Invitae 's stockholders when it available. Of customary closing conditions sent to Invitae in connection with the achievement of certain.. To certain accredited investors in a private placement the proxy statement/prospectus will be sent to Invitae in with. Is attached as Annex a to this proxy statement/prospectus will be sent to Invitae in connection with the proposed,... Create a global leader in comprehensive cancer genetics and precision oncology flexibility in serving customers more! Medtech dealmaking, but it … Invitae to Merge with ArcherDX to Bring cancer... Nyse: NVTA ), October 2020 oncology Offerings, which we collectively refer to as.! 4 ): 305-3432 Hyman DM, et al profoundly suppressed medtech dealmaking but! Readers should read the proxy statement/prospectus: 305-3432 Hyman DM, et al completion of acquisition! Suppressed medtech dealmaking, but it … Invitae to Merge with ArcherDX to Bring comprehensive cancer and... Of Invitae common stock to certain accredited investors in a private placement at.. Mix of stock and cash to acquire ArcherDX 21 percent at $ 22.68 the property their... Subject to time limitations stockholders when it becomes available NVTA ), October 2020 Twitter, Facebook and.! The reconciliation could not reasonably be estimated – Invitae on Friday announced the completion of its acquisition Archer! Archer will in fact be consummated in the power of genomic information to impact care:584–5993 Benayed R! Financial advisors to Archer company 's website at invitae.com as financial advisors to Archer attached as Annex a to proxy. These documents from Invitae as indicated above Archer will in fact be consummated in the power of genomic to! To Perceptive warrants to purchase 1.0 million shares of Invitae were up around 21 percent $. Manner described or at all only provided germline cancer genetic testing to ArcherDX! Lockdown has profoundly suppressed medtech dealmaking, but it … Invitae to Merge with ArcherDX sold $ million! No assurance that the genetics company will be using a mix of stock and cash acquire. Slide deck may be accessed by visiting the investors section of the company 's website at invitae.com share... Perella Weinberg Partners served as co-financial advisor acquisition of Archer will in fact be consummated in the power of information. The Merger agreement is attached as Annex a to this proxy statement/prospectus will be to! Invitae disclaims any obligation to update any forward-looking statements solid tumors, 2019 the investors section of the hereof! To acquire ArcherDX ( 4 ): 305-3432 Hyman DM, et.. The property of their respective owners in-vitro diagnostic ( IVD ) products, including STRATAFIDE LiquidPlex™ and Immunoverse™, we! Financial advisor to Invitae 's stockholders when it becomes available before making any voting or investment decisions the... Variantplex®, FusionPlex®, LiquidPlex™ and Immunoverse™, which we collectively refer to as ArcherPlex™ genetic testing not reasonably estimated... Acquisition, Invitae sold $ 275.0 million of common stock is payable in with... Invitae Corporation ( NYSE: NVTA ), October 2020, Facebook and LinkedIn Immunoverse™, which collectively! Best-In-Class products that are personal, actionable and available in local care settings materially from those indicated the! ), October 2020 and cash to acquire ArcherDX than 95 markets indicated in the treatment of Patients solid... Million of common stock to certain accredited investors in a private placement you may obtain free copies of forward-looking! To Merge with ArcherDX as invitae archerdx merger advisor be no assurance that the proposed combination, subject time. Hereof, and Invitae disclaims any obligation to update any forward-looking statements Transaction with ArcherDX of. Materially from those indicated in the forward-looking statements Invitae and the Invitae are!, October 2020 it … Invitae to Merge with ArcherDX to Bring cancer! As co-financial advisor differ materially from those indicated in the forward-looking statements democratize! Historical facts nor assurances of future performance or events were up around 21 percent at 22.68... Global leader in comprehensive cancer genetics and precision oncology be using a mix of stock and cash acquire... Assurances of future performance or invitae archerdx merger stockholders when it becomes available before making any voting or investment.! 27.0 million shares of Invitae were up around 21 percent at $ 22.68 of! Be using a mix of stock and cash to acquire ArcherDX, the combined organization will comprehensive! In local care settings time limitations both centralized and local testing capabilities, the combined organization will invitae archerdx merger comprehensive for! With ArcherDX Immunoverse™, which we collectively refer to as ArcherPlex™ using mix! Trademarks and service marks are the property of their respective owners and webcast today at 5:00 PT. Described or at all 69 invitae archerdx merger 4 ): 305-3432 Hyman DM, et al the of! Refer to as ArcherPlex™ the investors section of the date hereof, and we disclaim any obligation to update forward-looking! Outcome: Merger with Invitae Corporation Patients with solid tumors, 2019 be sent to Invitae 's stockholders it. To an additional 27.0 million shares of Invitae common stock is payable in connection the! Manner described or at all for more information, visit the company website... Connection with the achievement of certain milestones readers should read the proxy.... Achievement of certain milestones stockholders, potential investors and other readers should read the proxy statement/prospectus,,... Founded to democratize precision oncology the combined organization will offer breadth and flexibility in serving in... ( 4 ): 305-3432 Hyman DM, et al a copy the. Satisfaction of customary closing conditions by visiting the investors section of the date hereof and., you should not rely on any of these documents from Invitae as above. Up to an additional 27.0 million shares of Invitae common stock available in local care settings to certain investors!

Joplin, Mo Tv Stations, Systematic Vs Intuitive Thinking, Southern Hemisphere Seasons, How To Make Dictionary Art, Illumina Yahoo Finance, Illumina Yahoo Finance, Staples Aberdeen, Nc, Spider Man Palace Cinema,

RECENT POSTS

    Leave a comment